Human head and neck squamous cell carcinoma cells are both targets and effectors for the angiogenic cytokine, VEGF

Journal of Cellular Biochemistry

Volumn 105, Issue 5, 2008, Pages 1202-1210

  Tong, Meng ^a   Lloyd, Brandon ^a   Pei, Ping ^a   Mallery, Susan R ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Flt 1; Head and neck squamous cell carcinoma; Intracellular signaling; KDR; VEGF

Indexed keywords

CYTOKINE; GELATINASE; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; REACTIVE OXYGEN METABOLITE; SMALL INTERFERING RNA; VASCULOTROPIN; VASCULOTROPIN 165; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ARTICLE; CANCER INVASION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; ENZYME RELEASE; GENETIC TRANSFECTION; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; MITOGENESIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA;

CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; CELLS, CULTURED; CYTOKINES; HEAD AND NECK NEOPLASMS; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHORYLATION; REACTIVE OXYGEN SPECIES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 57149099179     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.21920     Document Type: Article

References (45)

1. Artese L, Rubini C, Ferrero G, Fioroni M, Santinelli A, Piattelli A. 2001. Microvessel density (MVD) and vascular endothelial growth factor expression (VEGF) in human oral squamous cell carcinoma. Anticancer Res 21:689-695.
2. Bassi DE, Mahloogi H, Lopez De Cicco R, Klein-Szanto A. 2003. Increased furin activity enhances the malignant phenotype of human head and neck cancer cells. Am J Pathol 162:439-447.
3. Bates RC, Goldsmith JD, Bachelder RE, Brown C, Shibuya M, Oettgen P, Mercurio AM. 2003. Flt-1-dependent survival characterizes the epithelial-mesenchymal transition of colonic organoids. Curr Biol 13:1721-1727.
4. Breier G, Clauss M, Risau W. 1995. Coordinate expression of vascular endothelial growth factor receptor-1 (flt-1) and its ligand suggests a paracrine regulation of murine vascular development. Dev Dyn 204:228-239.
5. Chin D, Boyle GM, Porceddu S, Theile DR, Parsons PG, Coman WB. 2006. Head and neck cancer: Past, present and future. Expert Rev Anticancer Ther 6:1111-1118.
6. Christiansen JJ, Rajasekaran AK. 2006. Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res 66:8319-8326.
7. Chung CH, Parker JS, Ely K, Carter J, Yi Y, Murphy BA, Ang KK, El-Naggar AK, Zanation AM, Cmelak AJ, Levy S, Slebos RJ, Yarbrough WG. 2006. Gene expression profiles identify epithelial-to-mesenchymal transition and activation of nuclear factor-kappaB signaling as characteristics of a high-risk head and neck squamous cell carcinoma. Cancer Res 66:8210-8218.
8. Colavitti R, Pani G, Bedogni B, Anzevino R, Borrello S, Waltenberger J, Galeotti T. 2002. Reactive oxygen species as downstream mediators of angiogenic signaling by vascular endothelial growth factor receptor-2/KDR. J Biol Chem 277:3101-3108.
9. Ferrara N. 2005. VEGF as a therapeutic target in cancer. Oncology 69 (Suppl 3): 11-16.
10. Ferrara N, Gerber HP, LeCouter J. 2003. The biology of VEGF and its receptors. Nat Med 9:669-676.
11. Finkel T. 1998. Oxygen radicals and signaling. Curr Opin Cell Biol 10:248-253.
12. Folkman J. 1992. The role of angiogenesis in tumor growth. Semin Cancer Biol 3:65-71.
13. Fujita K, Sano D, Kimura M, Yamashita Y, Kawakami M, Ishiguro Y, Nishimura G, Matsuda H, Tsukuda M. 2007. Anti-tumor effects of bevacizumab in combination with paclitaxel on head and neck squamous cell carcinoma. Oncol Rep 18:47-51.
14. Fury MG, Zahalsky A, Wong R, Venkatraman E, Lis E, Hann L, Aliff T, Gerald W, Fleisher M, Pfister DG. 2007. A phase II study of SU5416 in patients with advanced or recurrent head and neck cancers. Invest New Drugs 25:165-172.
15. Gotzmann J, Mikula M, Eger A, Schulte-Hermann R, Foisner R, Beug H, Mikulits W. 2004. Molecular aspects of epithelial cell plasticity: Implications for local tumor invasion and metastasis. Mutat Res 566:9-20.
16. Gourin CG, McAfee WJ, Neyman KM, Howington JW, Podolsky RH, Terris DJ. 2005. Effect of comorbidity on quality of life and treatment selection in patients with squamous cell carcinoma of the head and neck. Laryngoscope 115:1371-1375.
17. Hanahan D, Folkman J. 1996. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353-364.
18. Hasina R, Lingen MW. 2001. Angiogenesis in oral cancer. J Dent Educ 65:1282-1290.
19. Huh JI, Calvo A, Stafford J, Cheung M, Kumar R, Philp D, Kleinman HK, Green JE. 2005. Inhibition of VEGF receptors significantly impairs mammary cancer growth in C3(1)/Tag transgenic mice through antiangiogenic and non-antiangiogenic mechanisms. Oncogene 24:790-800.
20. Johnstone S, Logan RM. 2006. The role of vascular endothelial growth factor (VEGF) in oral dysplasia and oral squamous cell carcinoma. Oral Oncol 42:337-342.
21. Kanno S, Oda N, Abe M, Terai Y, Ito M, Shitara K, Tabayashi K, Shibuya M, Sato Y. 2000. Roles of two VEGF receptors, flt-1 and KDR, in the signal transduction of VEGF effects in human vascular endothelial cells. Oncogene 19:2138-2146.
22. Kyzas PA, Stefanou D, Batistatou A, Agnantis NJ. 2005. Potential autocrine function of vascular endothelial growth factor in head and neck cancer via vascular endothelial growth factor receptor-2. Mod Pathol 18:485-494.
23. Lalla RV, Boisoneau DS, Spiro JD, Kreutzer DL. 2003. Expression of vascular endothelial growth factor receptors on tumor cells in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 129:882-888.
24. Lee TH, Seng S, Sekine M, Hinton C, Fu Y, Avraham HK, Avraham S. 2007. Vascular endothelial growth factor mediates intracrine survival in human breast carcinoma cells through internally expressed VEGFR1/FLT1. PLoS Med 4:e186.
25. Millauer B, Wizigmann-Voos S, Schnurch H, Martinez R, Møller NP, Risau W, Ullrich A. 1993. High affinity VEGF binding and developmental expression suggest flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 72:835-846.
26. Moriyama M, Kumagai S, Kawashiri S, Kojima K, Kakihara K, Yamamoto E. 1997. Immunohistochemical study of tumour angiogenesis in oral squamous cell carcinoma. Oral Oncol 33:369-374.
27. Naumov GN, Akslen LA, Folkman J. 2006. Role of angiogenesis in human tumor dormancy: Animal models of the angiogenic switch. Cell Cycle 5:1779-1787.
28. Neuchrist C, Erovic BM, Handisurya A, Steiner GE, Rockwell P, Gedlicka C, Burian M. 2001. Vascular endothelial growth factor receptor 2 (VEGFR2) expression in squamous cell carcinomas of the head and neck. Laryngoscope 111:1834-1841.
29. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. 2006. VEGF receptor signalling - In control of vascular function. Nat Rev Mol Cell Biol 7:359-371.
30. 121 and regulates endothelial cell migration and sprouting. J Biol Chem 282:24049-24056.
31. Pei P, Horan MP, Hille R, Hemann CF, Schwendeman SP, Mallery SR. 2006. Reduced nonprotein thiols inhibit activation and function of MMP-9: Implications for chemoprevention. Free Radic Biol Med 41:1315-1324.
32. Rhee SG, Bae YS, Lee SR, Kwon J. 2000. Hydrogen peroxide: A key messenger that modulates protein phosphorylation through cysteine oxidation. Sci STKE 2000:PE1.
33. Ribatti D, Nico B, Crivellato E, Roccaro AM, Vacca A. 2007. The history of the angiogenic switch concept. Leukemia 21:44-52.
34. Rodrigo KA, Rawal Y, Renner RJ, Schwartz SJ, Tian Q, Larsen PE, Mallery SR. 2006. Suppression of the tumorigenic phenotype in human oral squamous cell carcinoma cells by an ethanol extract derived from freeze-dried black raspberries. Nutr Cancer 54:58-68.
35. Sano D, Kawakami M, Fujita K, Kimura M, Yamashita Y, Ishiguro Y, Nishimura G, Matsuda H, Tsukuda M. 2007. Antitumor effects of ZD6474 on head and neck squamous cell carcinoma. Oncol Rep 17:289-295.
36. St John MA, Abemayor E, Wong DT. 2006. Recent new approaches to the treatment of head and neck cancer. Anticancer Drugs 17:365-375.
37. Stewart M, Turley H, Cook N, Pezzella F, Pillai G, Ogilvie D, Cartlidge S, Paterson D, Copley C, Kendrew J, Barnes C, Harris AL, Gatter KC. 2003. The angiogenic receptor KDR is widely distributed in human tissues and tumours and relocates intracellularly on phosphorylation: An immunohistochemical study. Histopathology 43:33-39.
38. Takahashi T, Shibuya M. 1997. The 230 kDa mature form of KDR/Flk-1 (VEGF receptor-2) activates the PLC-gamma pathway and partially induces mitotic signals in NIH3T3 fibroblasts. Oncogene 14:2079-2089.
39. Thiery JP, Chopin D. 1999. Epithelial cell plasticity in development and tumor progression. Cancer Metastasis Rev 18:31-42.
40. Weigand M, Hantel P, Kreienberg R, Waltenberger J. 2005. Autocrine vascular endothelial growth factor signalling in breast cancer: Evidence from cell lines and primary breast cancer cultures in vitro. Angiogenesis 8:197-204.
41. Wilson RF, Morse MA, Pei P, Renner RJ, Schuller DE, Robertson FM, Mallery SR. 2003. Endostatin inhibits migration and invasion of head and neck squamous cell carcinoma cells. Anticancer Res 23:1289-1295.
42. Wu Y, Hooper AT, Zhong Z, Witte L, Bohlen P, Rafii S, Hicklin DJ. 2006. The vascular endothelial growth factor receptor (VEGFR-1) supports growth and survival of human breast carcinoma. Int J Cancer 119:1519-1529.
43. Xia C, Meng Q, Liu LZ, Rojanasakul Y, Wang XR, Jiang BH. 2007. Reactive oxygen species regulate angiogenesis and tumor growth through vascular endothelial growth factor. Cancer Res 67:10823-10830.
44. Yang AD, Camp ER, Fan F, Shen L, Gray MJ, Liu W, Somcio R, Bauer TW, Wu Y, Hicklin DJ, Ellis LM. 2006. Vascular endothelial growth factor receptor-1 activation mediates epithelial to mesenchymal transition in human pancreatic carcinoma cells. Cancer Res 66:46-51.
45. Zhang Q, Bhola NE, Lui VW, Siwak DR, Thomas SM, Gubish CT, Siegfried JM, Mills GB, Shin D, Grandis JR. 2007. Antitumor mechanisms of combined gastrin-releasing peptide receptor and epidermal growth factor receptor targeting in head and neck cancer. Mol Cancer Ther 6:1414-1424.